This Article Abstract Free Full Text (Free PDF) Free Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Neutel, J. M Articles by Smith, D. Search for Related Content PubMed PubMed Citation Articles by Neutel, J. M Articles by Smith, D. Social Bookmarking                         What's this?

Comparison of Monotherapy with Irbesartan 150 mg or Amlodipine 5 mg for Treatment of Mild-to-Moderate Hypertension

Orange County Research Center, Tustin, California, USA, jmneutel{at}aol.com

F Wilford Germino

Department of Internal Medicine, University of Chicago, Chicago, Illinois, USA

David Smith

Orange County Research Center, Tustin, California, USA

Objective. The primary objective of this study was to compare the antihypertensive efficacy of the angiotensin II receptor blocker irbesartan 150 mg and the calcium channel blocker amlodipine 5 mg in the treatment of patients with seated diastolic blood pressure (DBP) 95—110 mmHg.

Design. Multicentre, randomised, double-blind, comparative pilot study.

Methods. Subjects were 18—65 years of age, with DBP 95—110 mmHg, and of non-African American origin. Following a three-week, single-blind, placebo lead-in period, 181 subjects were randomised in a 1:1 ratio to receive once-daily irbesartan 150 mg (n=89) or amlodipine 5 mg (n=92) for four weeks. Trough (24±3 hours post-dosing) BP measurements were obtained at baseline and at Weeks 2 and 4 under standardised, controlled conditions. Response was defined as DBP <90 mmHg or a reductionfrom baseline of 10 mmHg.

Results. After four weeks of treatment, the mean (±SE) decrease from baseline in DBP was 9.4±0.6 mmHg in the irbesartan group vs. 9.6±0.6 mmHg in the amlodipine group (p=0.806). The mean decrease from baseline in seated systolic BP was 12.2±1.0 mmHg in the irbesartan group vs. 12.0±1.0 mmHg in the amlodipine group (p=0.885). Overall, 62% of subjects in the irbesartan group and 63% in the amlodipine group had a response (p=0.609), and 54% and 56% of patients (p=0.596), respectively, had their DBP normalised (<90 mmHg). Adverse events were reported by 21.3% of patients receiving irbesartan and 20.7% receiving amlodipine.

Conclusions. Irbesartan 150 mg demonstrated comparable efficacy to amlodipine 5 mg, thereby confirming its value as an antihypertensive treatment option in non-African American patients with DBP 95—110 mmHg.

Key Words: Irbesartan • Amlodipine • Ambulatory BP monitoring

References

• Chobanian AV, Bakris GL, Black HR et al, and the National High Blood Pressure Education Program Coordinating Committee. Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension 2003;42: 1206-52.[Abstract/Free Full Text]
• Levine CB, Fahrbach KR, Frame D. et al. Effect of amlodipine on systolic blood pressure. Clin Ther 2003;25:35-57.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• . Haria M., Wagstaff AJ Amlodipine. A reappraisal of its pharmacological properties and therapeutic use in cardiovascular disease. Drugs 1995;50:560-86.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Norvasc® (amlodipine besylate) tablets. Prescribing information. In: Physician's Desk Reference; 2004:2615-19.
• Eberhardt RT, Kevak RM, Kang PM, Frishman WH Angiotensin II receptor blockade: an innovative approach to cardiovascular pharmacotherapy. J Clin Pharmacol 1993;33:1023-38.[Abstract]
• Neutel JM Safety and efficacy of angiotensin II receptor antagonists. Am J Cardiol 1999;84:13K-17K.[Web of Science][Medline] [Order article via Infotrieve]
• Dina R., Jafari M. Angiotensin II-receptor antagonists: an overview. Am J Health Syst Pharm 2000;57:1231-41.[Abstract/Free Full Text]
• Pylypchuk GB ACE inhibitor- versus angiotensin II 1998;32:1060-6. blocker-induced cough and angioedema. Ann Pharmacother
• Birkenhager WH, de Leeuw PW Non-peptide angiotensin type 1 receptor antagonists in the treatment of hypertension. J Hypertens 1999;17:873-81.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Burnier M., Brunner HR Comparative antihypertensive effects of angiotensin II receptor antagonists. J Am Soc Nephrol 1999;10(suppl 12):S278-S282.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Israili ZH, Hall WD Cough and angioneurotic edema associated with angiotensin-converting enzyme inhibitor therapy. A review of the literature and pathophysiology. Ann Intern Med 1992;117:234-42.
• Lacourcière Y., Brunner H., Irwin R. et al and the Losartan Cough Study Group. Effects of modulators of the renin-angiotensin-aldosterone system on cough. J Hypertens 1994;12:1387-93.[Web of Science][Medline] [Order article via Infotrieve]
• Croom KF, Curran MP, Goa KL, Perry CM Irbesartan: a review of its use in hypertension and in the management of diabetic nephropathy. Drugs 2004;64:999-1028.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Reeves RA, Lin CS, Kassler-Taub K., Pouleur H. Dose-related efficacy of irbesartan for hypertension: an integrated analysis. Hypertension 1998;31:1311-16.[Abstract/Free Full Text]
• Pool JL, Guthrie RM, Littlejohn TW, 3rd et al. Dose-related antihypertensive effects of irbesartan in patients with mild-to-moderate hypertension. Am J Hypertens 1998;11:462-70.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 2002;288:2981-97.[Abstract/Free Full Text]
• Jamerson K., DeQuattro V. The impact of ethnicity on response to antihypertensive therapy. Am J Med 1996; 101(3A):22S-32S.[Medline] [Order article via Infotrieve]
• Saunders E., Weir MR, Kong BW et al. A comparison of the efficacy and safety of a beta-blocker, a calcium channel blocker, and a converting enzyme inhibitor in hypertensive blacks. Arch Intern Med 1990;150:1707-13.[Abstract/Free Full Text]
• Cushman WC, Reda DJ, Perry HM, Williams D., Abdellatif M., Materson BJ, for the Department of Veterans Affairs Cooperative Study Group on Antihypertensive Agents. Regional and racial differences in response to antihypertensive medication use in a randomized controlled trial of men with hypertension in the United States. Arch Intern Med 2000;160:825-31.[Abstract/Free Full Text]
• Julius S., Kjeldsen SL, Weber MA et al. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomized trial. The Lancet. Published online June 14, 2004. http://image.thelancet.com/extras/04let5020web.pdf
• Elmfeldt D., Olofsson B., Meredith P. The relationships between dose and antihypertensive effect of four AT1-receptor blockers. Differences in potency and efficacy. Blood Press 2002;11:293-301.
• Oparil S., Williams D., Chrysant SG, Marbury TC, Neutel J. Comparative efficacy of olmesartan, losartan, valsartan, and irbesartan in the control of essential hypertension. J Clin Hypertens 2001;3:283-91, 318.
• Mancia G., Korlipara K., van Rossum P., Villa G., Silvert B. An ambulatory blood pressure monitoring study of the comparative antihypertensive efficacy of two angiotensin II receptor antagonists, irbesartan and valsartan. Blood Press Monit 2002;7:135-42.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Kassler-Taub K., Littlejohn T., Elliott W., Ruddy T., Adler E. for the Irbesartan/Losartan Study Investigators. Comparative efficacy of two angiotensin II receptor antagonists, irbesartan and losartan in mild-to-moderate hypertension. Am J Hypertens 1998;11:445-53.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Bobrie G., Giacomino A., Postel-Vinay N., Moulin C., Asmar R. COmparative Study of efficacy of Irbesartan/ hydrochlorothiazide with valsartan/hydrochlorothiazide using home blood pressure Monitoring in the treAtment of mild to moderate hypertension (COSIMA). Presented at the 24th Meeting of the French Society of Arterial Hypertension, Paris, France. 16-17 December, 2004.
• Lewis EJ, Hunsicker LG, Clarke WR et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engel J Med 2001;345:851-60.[CrossRef]
• American Heart Association. Heart Disease and Stroke Statistics - 2005 Update. In. Dallas, Texas: American Heart Association; 2005.

Journal of Renin-Angiotensin-Aldosterone System, Vol. 6, No. 2, 84-89 (2005)
DOI: 10.3317/jraas.2005.014


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?

This Article Abstract Free Full Text (Free PDF) Free Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Neutel, J. M Articles by Smith, D. Search for Related Content PubMed PubMed Citation Articles by Neutel, J. M Articles by Smith, D. Social Bookmarking                         What's this?